SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: AuBug who wrote (187)8/10/2003 2:38:45 PM
From: Hank  Read Replies (2) of 684
 
Thanks for the concise explanation. After you mentioned it the last time, I asked around to find out why some large pharmaceutical companies were reluctant to use this approach versus the hybrid mouse. The answer was, "Because nobody has been able to develop an antibody therapy yet using phage display." I can't say if this is true or not but the answer was not surprising. Big drug companies tend to be very superstitious about these things and will only invest the time and money if somebody has already used the approach to bring a drug to market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News